A Single-arm, Open-label Phase IV Study to Evaluate the Effectiveness of Sotatercept in Improving Pulmonary Vascular Recruitment in Patients With Pulmonary Arterial Hypertension (PAH)

The goal of this clinical trial is to determine whether sotatercept is effective in improving diffusing capacity in patients with pulmonary arterial hypertension.
Participants will be asked to:
* Take Sotatercept every 21 days (±3 days)
* Each participant will be enrolled in the study for 29 Weeks
* Visit the clinic 15 times
* Have a physical exam
* Perform assessments of lung function and exercise tests
* Have an ultrasound of their heart
* Have blood draws done at regular intervals
The main objectives of the study are:
Primary objective: To assess whether sotatercept will improve recruitment of diffusing membrane capacity (DM) with exercise.
Secondary objective: To identify components of the diffusing capacity that respond to treatment with sotatercept in pulmonary arterial hypertension.

开始日期2025-09-30

申办/合作机构

University of Alberta

[+2]

CTR20252035

/ Recruiting临床2期

一项在接受标准治疗的动脉性肺动脉高压（PAH）受试者中评价Sotatercept（MK-7962）按体重区间给药的安全性和耐受性的开放性扩展研究

评价sotatercept按体重区间给药的长期安全性和耐受性

开始日期2025-06-05

申办/合作机构

默沙东研发（中国）有限公司

[+2]

NCT06930664

/ Recruiting临床1期

A Phase 1 Clinical Study in Healthy Females of Nonchildbearing Potential to Compare the Pharmacokinetics of Sotatercept (MK-7962) Administered as a Liquid Formulation in an Autoinjector Versus the Lyophilized Formulation

The goal of the study is to learn what happens to different forms of sotatercept medications in a healthy person's body over time. Researchers want to know if there is a difference in the healthy person's body when different forms of sotatercept medications are given.

开始日期2025-05-16

申办/合作机构

Merck Sharp & Dohme LLC

100 项与索特西普相关的临床结果

登录后查看更多信息

100 项与索特西普相关的转化医学

登录后查看更多信息

100 项与索特西普相关的专利（医药）

登录后查看更多信息

181

项与索特西普相关的文献（医药）

2025-09-01·VASCULAR PHARMACOLOGY

Clinical outcomes and safety of sotatercept in pulmonary arterial hypertension: A systematic review and meta-analysis of randomized controlled trials

Review

作者: Ezenna, Chidubem ; Jenil-Franco, Ancy ; Abdulelah, Mohammad ; Dahhan, Talal ; Chi, Kuan-Yu ; Joseph, Meghna ; Jamouss, Kevin T ; Krishna, Mrinal Murali

INTRODUCTION:

Pulmonary arterial hypertension (PAH) remains a life-threatening condition characterized by high morbidity and mortality. However, recent therapeutic advancements have offered a paradigm shift in terms of therapeutic goals.

METHODS:

We conducted a systematic review and meta-analysis of RCTs assessing clinical outcomes and safety of sotatercept when compared to placebo in PAH. Searches of Pubmed and Cochrane Central databases were performed through April 2025. The primary outcome was all-cause mortality. Secondary outcomes included improvements in 6MWD, WHO functional class, hemodynamics, NT-proBNP, and serious adverse events. Data were pooled using a random-effects model, with certainty of evidence assessed via GRADE methodology.

RESULTS:

Three RCTs comprising 601 patients were included. There was a non-significant trend toward reduced mortality (RR 0.49; 95 % CI 0.16 to 1.46; p = 0.11). Sotatercept was associated with significant improvements in 6MWD (MD 37.99 m; 95 % CI 6.47 to 69.52; p = 0.04) and WHO functional class (RR 2.04; 95 % CI 1.79 to 2.31; p = 0.002). Hemodynamic improvements included reductions in PVR (MD -237.73 dyn·s/cm⁵; 95 % CI -367.02 to -1.8.43; p = 0.02) and mPAP (MD -14.88 mmHg; 95 % CI -24.76 to -4.99; p = 0.02). Serious adverse events were similar (RR 0.79; 95 % CI 0.51 to 1.23; p = 0.15).

CONCLUSION:

Sotatercept significantly improves functional and hemodynamic outcomes in PAH, with a favorable safety profile. While mortality benefits remain uncertain, these findings support its clinical utility as an emerging therapy in PAH.

2025-08-22·Current Vascular Pharmacology

Significant Stagnancy in the Search and Use of New Antiarrhythmic Agents With Some Recent Beams of Hope

Article

作者: Manolis, Antonis, A. ; Vouliotis, Apostolos ; A. Manolis, Theodora ; Manolis, Antonis S.

Abstract::

Over the last few decades, there has been noteworthy long-lasting stagnancy in the field of antiarrhythmic drugs (AAD), with the development of novel AAD notably declining over the years. Although ablation therapy has dominated, there remains an unmet need for effective and safe antiarrhythmic therapy in those choosing a conservative approach and those failing the ablation procedure( s). Also, in patients with life-threatening ventricular arrhythmias, in the era of the implantable cardioverter defibrillator dominance, many patients require effective and safe AAD therapy to mitigate the recurrence of arrhythmias and the delivery of painful and unpleasant device shocks. The repurposing and reformulation of current drugs in circulation for novel therapeutic uses may provide new avenues for developing antiarrhythmic treatments that can assist in curtailing cardiac arrhythmia- associated morbidity and mortality, and ameliorate the quality of life for millions of patients. Stressful factors may lead to endothelial dysfunction and a surge in blood pressure, contributing to the emergence of cardiac arrhythmogenic effects, including myocardial fibrosis and remodeling of structural, ion channels, and connexin 43 channels, with consequent dysfunction. Agents influencing this latter protein may have cardioprotective and potentially antiarrhythmic effects. In this review of new antiarrhythmic agents, the advantages of sodium-glucose co-transporter inhibitors, and also those of pirfenidone, ranolazine, sotatercept, mirabegron, nintedanib, and melatonin are discussed. Some of these agents have been approved for other indications and repurposed for use in managing arrhythmias. Finding novel antiarrhythmic therapeutic approaches may be challenging for further research.

2025-08-07·EUROPEAN RESPIRATORY JOURNAL

Pericardial effusion in sotatercept phase 3 trials: insights from STELLAR and ZENITH.

Letter

作者: Hoeper, Marius M ; Gomberg-Maitland, Mardi ; Loureiro, Maria José ; Mackenzie, Harald S ; Waxman, Aaron B ; Humbert, Marc ; Preston, Ioana R ; Shi, Yaru ; Lin, Jianxin ; McLaughlin, Vallerie V

375

项与索特西普相关的新闻（医药）

2025-09-01

·默沙东中国

默沙东将在2025年欧洲心脏病学会年会发布心血管疾病领域最新研究进展

默沙东将在2025年欧洲心脏病学会年会发布心血管疾病领域最新研究进展涉及动脉粥样硬化性心血管疾病（ASCVD）、肺动脉高压（PH）和射血分数降低型心力衰竭（HFrEF）等多种严重心血管疾病的全新真实世界证据和临床试验数据美国新泽西州罗威市，2025年8月26日——默沙东（默沙东是美国新泽西州罗威市默克公司的公司商号）宣布，公司将在2025年8月29日至9月1日于西班牙马德里举行的2025年欧洲心脏病学会（ESC）年会上发布最新临床试验和实效研究数据。此次大会上发布的数据涵盖默沙东在动脉粥样硬化性心血管疾病（ASCVD）、肺动脉高压（PH）以及射血分数降低型心力衰竭（HFrEF）等领域的最新研究进展。 Eliav Barr博士默沙东实验室高级副总裁全球临床开发负责人兼首席医学官 “ 全球范围内心血管疾病仍然是首要死亡原因，默沙东致力于通过研究和创新科学应对这一紧迫的公共卫生挑战。今年大会上所展示的数据体现了我们持续推动心血管研究的承诺，以期为全球患者带来新的希望。 ” 默沙东将有两场关于ASCVD患者治疗模式和疾病负担的口头报告。第一场报告基于一项为期10年的全国性登记数据，评估了有或无心肌梗死患者的临床和经济负担；第二场报告将探讨在大规模ASCVD患者群体中降脂治疗的时间趋势。这些数据展现了默沙东对ASCVD患者研究的持续投入，并发掘在真实世界环境中改善疾病管理的机会。大会期间，sotatercept-csrk[1]用于肺动脉高压的临床试验也将公布更新信息，包括II期CADENCE研究的研究依据和设计，评估用于伴有保留射血分数心力衰竭（HFpEF）的联合混合型毛细血管后性肺动脉高压（Cpc-PH）成人患者；以及ZENITH研究数据，评估sotatercept-csrk对高风险肺动脉高压（PAH）患者血流动力学的影响。默沙东还将有两场热线口头报告（hot line oral presentation）和两场补充海报展示，公布来自评估维立西呱用于HFrEF成人患者的VICTOR研究、VICTOR研究与VICTORIA研究的合并分析、以及真实世界分析的数据。关于ESC大会期间公司支持的专题研讨会：默沙东将在会议期间举办三场专题研讨会。8月31日星期日上午9:15至10:00（美国东部时间）/15:15至16:00（中欧夏令时间），在北会议中心Yerevan会议室举办的研讨会将聚焦LDL-C累积暴露与ASCVD风险连续性视角对高脂血症临床管理的影响，以及ASCVD患者早期及更低LDL-C目标达成对预防心血管事件的重要性。另外两场研讨会主题将聚焦于通过逆向重塑和右心功能改善治疗肺动脉高压（8月31日9:15-10:00，Algiers会议室，7号厅），以及心血管疾病患者倡导活动，探讨心血管疾病中的障碍与挑战（8月29日4:00-4:45，Nicosia会议室，北会议中心）。此外，默沙东还是此次ESC心血管健康检查（ESC Cardiovascular Health Check）的支持方之一。ESC年会现场参会者可免费参与包括总胆固醇、LDL胆固醇、脂蛋白(a)、甘油三酯、糖化血红蛋白（HbA1c）、体质指数（BMI）、血压等多项指标的综合血液检测心血管风险筛查。在ESC年会上公布的关键摘要数据包括：动脉粥样硬化性心血管疾病 ASCVD Temporal trends in lipid-lowering therapy utilization among ASCVD patients: a large-scale database analysis. M. Goldberg Abstract #83219, Oral abstract session : Friday, August 29, 3:30 a.m. ET/9:30 a.m. CEST Clinical and economic burden of patients with and without myocardial infarction: a contemporary nationwide 10-year registry comparison. C. Reitan Abstract #82314, Oral abstract session : Sunday, August 31, 7:15 a.m. ET/13:15 p.m. CEST 肺动脉高压 PH Rationale and design of the CADENCE trial: Evaluating sotatercept in Cpc-PH secondary to HFpEF. A. Urbinati Abstract #83974, Poster session : Monday, September 1, 4:15 – 4:45 a.m. ET/10:00 – 10:45 a.m. CEST Sotatercept Improves Hemodynamics in High-Risk Pulmonary Arterial Hypertension (PAH): Results from ZENITH Trial. V. McLaughlin Abstract #7382, Poster session: Saturday, August 30, 6:30 – 7:15 a.m. ET; 12:30 – 13:15 p.m. CEST 心力衰竭 Heart Failure Residual risk of hospitalization & all-cause mortality among patients with heart failure with reduced ejection fraction without worsening heart failure who received guideline-directed medical therapy. A. Stevenson Abstract #85697, Moderated ePoster session : Friday, August 29, 3:15 – 4:00 a.m. ET/9:15 – 10:00 a.m. CEST Dose titration among patients receiving vericiguat in real-world clinical practice and association with clinical outcomes and health care resource use. A. Ambrosy Abstract #85842, Moderated ePoster session : Friday, August 29, 3:15 – 4:00 a.m. ET/9:15 – 10:00 a.m. CEST Guideline-directed medication therapy use among patients with HFrEF receiving vericiguat : comparing findings from a real-world study to clinical trials. A. Ambrosy Abstract #85837, Moderated ePoster session : Friday, August 29, 3:15 – 4:00 a.m. ET/9:15 – 10:00 a.m. CEST VICTOR: Vericiguat Global Study in Participants with Chronic Heart Failure. F. Zannad Abstract #7316, Hot line oral session: Saturday, August 30, 2:33 a.m. ET/8:33 a.m. CEST VICTOR: Vericiguat Global Study in Participants with Chronic Heart Failure and VICTORIA: Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction. J. Butler Abstract #7319, Hot line oral session : Saturday, August 30, 2:43 a.m. ET/8:43 a.m. CEST Effect of vericiguat on mortality in ambulatory patients with heart failure and reduced ejection fraction : VICTOR Trial Prespecified Analysis. J. Butler Abstract #7315, Moderated ePoster session: Monday, September 1, 5:15 – 6:00 a.m. ET/11:15 a.m. – 12:00 p.m. CEST Effect of vericiguat on heart failure hospitalisation events in ambulatory patients with heart failure and reduced ejection fraction : VICTOR Trial Prespecified Analysis. F. Zannad Abstract #7314, Moderated ePoster session : Monday, September 1, 5:15 – 6:00 a.m. ET/11:15 a.m. – 12:00 p.m. CEST 关于默沙东在心血管领域的承诺默沙东在心血管疾病领域拥有深厚的积淀和持续的创新动力。自60多年前推出首款心血管治疗药物以来，我们始终致力于推动科学进步，深入探索心血管相关疾病的本质。心血管疾病依然是全球最严峻的健康挑战之一，每年约有1900万人因此失去生命。作为行业的创新引领者，默沙东始终坚持科学卓越，贯穿新药研发、审批和全生命周期管理的每一个阶段。我们积极与全球心血管及肺部疾病领域的专家紧密合作，推动前沿研究不断取得突破，努力为全球患者带来切实改善健康的解决方案。我们坚信，通过不断的科学创新与合作，能够为人类健康事业作出更大贡献。参考文献： 1. 截至目前，sotatercept-csrk尚未获得中国国家药品监督管理（NMPA）的批准关于拜耳与默沙东的全球合作 2014年10月，拜耳与默沙东（默沙东是美国新泽西州罗威市默克公司的公司商号）在可溶性鸟苷酸环化酶（sGC）调节剂领域开展全球合作，全面评估这一治疗类别在未满足医疗需求领域的潜力。维立西呱由拜耳和默沙东共同开发。默沙东拥有维立西呱在美国的商业权利，拜耳拥有其在全球其他地区的独家商业权利。两家公司共同对等承担维立西呱的开发费用。关于默沙东在默沙东（默沙东是美国新泽西州罗威市默克公司的公司商号），我们齐心协力追求共同的目标：我们发挥前沿科学的力量，在全球范围内拯救生命、改善生活。130多年来，我们通过研发重要药物和疫苗，为全人类带来希望。我们致力成为顶尖的研究密集型生物制药公司——当下，我们正处于研发前线，推出创新解决方案，以推进人类和动物疾病的预防和治疗。我们建立了一个多元、包容的全球员工体系，以负责的态度经营每一天，确保所有人、所有社区都能有一个安全、可持续和健康的未来。更多信息，请访问www.msd.com，并在X（前身为Twitter）、LinkedIn和Youtube平台关注我们。关于默沙东中国中国是默沙东全球增长战略中至关重要的一部分。默沙东中国总部设在上海，同时在北京设有研发中心、在杭州、宁波和天津分别设有工厂，实现了研发、制造和商业运营三擎合一。我们全心全意，向中国大众提供高质量的创新药物、疫苗和服务，造福中国社会。更多信息，敬请访问默沙东中国官网，或关注默沙东中国在微信上的官方社交媒体账号。默沙东前瞻性声明默沙东是美国新泽西州罗威市默克公司的公司商号（下称“公司”）。本新闻稿包含根据《1995 年美国私人证券诉讼改革法案》之安全条款而做出的“前瞻性声明”。本文内容基于公司管理层当前的看法和预期，并且受制于可能出现的重大风险和不确定因素。默沙东不保证在研产品能获得所需的监管部门批准或取得商业成功。如果相关假设与现实有所出入、出现风险，或发生不确定情况，实际结果可与前瞻性声明中的预期有实质上的差异。风险和不确定因素包括但不仅限于一般行业情况与竞争、一般经济因素（包括利率与汇率浮动）、美国及其他国家制药行业监管以及医疗政策的影响、全球范围内控制医疗成本的趋势、技术发展、竞争对手获得的新产品与专利、新产品开发固有的挑战（包括获得监管部门批准）、默沙东对未来市场形势做出准确预测的能力、生产上的困难或迟延、国际经济金融状况不稳定与主权风险、对默沙东专利和其它创新产品保护的有效性的依赖程度，以及公司面临专利诉讼和/或监管行动的风险。默沙东没有义务就新信息、未来事件或其它原因对任何前瞻性声明进行公开的更新。尚有其它因素可能导致实际结果与前瞻性声明存在实质性差异，请参见默沙东2024年年报10-K报表以及公司在美国证券交易所备案的其它文件（可在美国证券交易所网站www.sec.gov上查阅）。

2025-08-07

·FiercePharma

Merck faced no competition in its $10B buyout of Verona

In its $10 billion acquisition of Verona Pharma last month, Merck was the only company that placed a bid on the British biotech. Merck pulled off its $10 billion buyout of Verona Pharma last month with little of the wheeling and dealing that typically accompanies a big-money acquisition in the biopharma industry.In fact, Merck was the only company that made an offer to Verona, according to a Securities and Exchange Commission filing by the British company on Monday, which detailed its negotiations leading up to the transaction.The lack of interest came despite Verona scoring a landmark FDA approval a year ago for Ohtuvayre, the first new medicine for chronic obstructive pulmonary disorder (COPD) in more than a decade.The treatment, which is administered twice daily with a hand-held nebulizer, earned an advantageous nod as the U.S. regulator signed off on it to be used as a monotherapy or in combination with other COPD maintenance drugs. It has drawn annual peak sales projections of up to $5 billion.Verona’s efforts to attract suitors began in early 2023, as it and New York City investment advisory firm Centerview Partners conducted outreach with drugmakers who might be interested in a partnership or an outright acquisition, according to the filing.Those attempts drew interest from just one unidentified company (not Merck), which met with Verona in July 2023 and signed a nondisclosure agreement. But the company never made Verona an offer.In December 2023, Verona and Centerview agreed to begin another round of outreach, which attracted no substantial interest for more than a year. Then, in February of this year, Merck told Verona that a nondisclosure agreement—which they had signed in 2020—had expired. The companies signed a new one, without a “standstill provision,” which allowed them to freely discuss potential business development opportunities.Over the next few months, Verona met several times with Merck’s Human Health International chief Joseph Romanelli. Among the topics they discussed were Merck owning rights to Ohtuvayre either inside or outside of the U.S.Similarly, in early June, more than one third party, according to the filing, sent Verona a nonbinding term sheet concerning a potential collaboration on Ohtuvayre. A nonbinding term sheet allows a company to explore a potential transaction without making an offer. Then, on July 3, Merck proposed to buy out Verona for $104 per share and placed a five-day deadline on the offer. Later that day, Verona’s share price closed at $91.53.Also that day, after a meeting with its board, Verona made a counteroffer of $112 per share, prompting Merck to respond with a $107 per-share offer. On the deadline, July 8, the companies agreed to the deal, which was a 23% markup on Verona’s price at market close on July 8 and a 39% premium on the company’s 60-day volume-weighted average price.The transaction is the second-largest in the biopharma industry this year after Johnson & Johnson’s $14.6 billion buyout of Intra-Cellular Therapies. A regulatory filing after that deal indicated that it happened over the course of just one month and that J&J placed the lone bid on the company, which has schizophrenia and bipolar disorder drug Caplyta in its portfolio, along with another highly touted antipsychotic candidate. Merck’s move is part of its strategy to compensate for the loss of patent protection later this decade for its cancer superstar Keytruda, which accounted for more than 50% of the company’s revenue in the second quarter.In 2021, Merck spent $11.5 billion for Acceleron and its pulmonary arterial hypertension treatment, now known commercially as Winrevair. Then in 2023, the New Jersey company ponied up $10.8 billion for Prometheus and its late-stage bowel disease candidate PRA023.In 2023, Merck lost out in a bid to acquire Seagen as Pfizer snapped up the antibody-drug conjugate specialist for $43 billion. The run-up to that deal involved two other unidentified companies in a bidding war that is much more typical of a large biopharma acquisition.

并购上市批准

2025-07-29

·BioPharmaDive

Merck plans spending shift to boost business beyond Keytruda

Dive Brief:Merck & Co. is launching a new cost-cutting program, announcing Tuesday a plan to redirect by the end of 2027 $3 billion away from older, slow-growth businesses to newly launched drugs and experimental medicines it hopes can drive faster revenue growth.The move comes as Merck prepares for generic competition to its cancer blockbuster Keytruda beginning in 2028 in the U.S. Research and development, sales and manufacturing functions will be affected as Merck seeks to support the newer drugs.Merck is already facing faltering topline sales as its second biggest drug, the HPV vaccine Gardasil, has struggled in China and Japan. CEO Rob Davis told investors that executives expect a return to growth in the second half of 2025, following a second quarter in which Merck recorded a 2% fall in sales compared with the same period one year ago.Dive Insight:In the companys second quarter earnings call, executives didnt go into detail about how spending within the company would shift. However, Davis dropped a hint that spending behind Keytruda would fall in favor of newer products like the cancer medicine Welireg or an experimental dual-acting drug licensed from LaNova Medicines.Were not looking to pull back on spending in oncology, he said. Its about reallocating our resources and focusing our resources so its not just about Keytruda. Youre going to see greater growth spend as you see Keytruda pull back.Pipeline products and newly launched drugs represent a $50 billion commercial opportunity by the mid-2030s, Mercks executives claim. Of that, new oncology medicines account for $25 billion in potential sales and new cardiometabolic drugs like Winrevair and an experimental cholesterol drug make up $15 billion, while HIV and immunology medicines are another $5 billion each, Davis said.Merck also recently agreed to buy Verona Pharma in a $10 billion deal that will add a newly approved lung disease drug to its pipeline.Still, Merck faces near-term challenges as it confronts falling sales from Gardasil. It has paused China shipments through at least the end of 2025, and also faces slowing revenue in Japan. Meanwhile, in the U.S., the Centers for Disease Control and Prevention may move to recommend a single dose of Gardasil rather than the two to three now used, further limiting sales.Total sales in the second quarter were $15.8 billion, down from $16.1 billion in the same period in 2024. Merck is forecasting 2025 sales of between $64.3 and $65.3 billion, compared with the $64.2 billion it recorded in 2024.Shares fell more than 3% in morning trading. '

疫苗

100 项与索特西普相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D09670	-	-	DB12118

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
抑郁症	加拿大	Merck Canada, Inc.	2024-08-01
肺动脉高压	美国	Merck Sharp & Dohme LLC	2024-03-26

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
家族性肺动脉高压	临床3期	美国	Acceleron Pharma, Inc.	2021-01-25
家族性肺动脉高压	临床3期	阿根廷	Acceleron Pharma, Inc.	2021-01-25
家族性肺动脉高压	临床3期	澳大利亚	Acceleron Pharma, Inc.	2021-01-25
家族性肺动脉高压	临床3期	比利时	Acceleron Pharma, Inc.	2021-01-25
家族性肺动脉高压	临床3期	巴西	Acceleron Pharma, Inc.	2021-01-25
家族性肺动脉高压	临床3期	加拿大	Acceleron Pharma, Inc.	2021-01-25
家族性肺动脉高压	临床3期	捷克	Acceleron Pharma, Inc.	2021-01-25
家族性肺动脉高压	临床3期	法国	Acceleron Pharma, Inc.	2021-01-25
家族性肺动脉高压	临床3期	德国	Acceleron Pharma, Inc.	2021-01-25
家族性肺动脉高压	临床3期	以色列	Acceleron Pharma, Inc.	2021-01-25

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04896008 (MK-7962-006 \| ZENITH, CTgov)	临床3期	家族性肺动脉高压 \| 肺动脉高压	173	Sotatercept (Sotatercept)	鹽獵鬱蓋憲窪夢構簾壓(築觸艱衊鬱獵顧積觸範) = 網醖鏇顧範膚鬱築鹹網觸壓繭窪網製積艱網鏇 (鏇網蓋鑰構範壓鑰夢簾, 窪網廠鏇築簾鬱顧鬱齋 ~ 積憲淵鹹積鏇膚積鹹觸) 更多	-	2025-08-22
				Placebo (Placebo)	鹽獵鬱蓋憲窪夢構簾壓(築觸艱衊鬱獵顧積觸範) = 鏇構窪範襯遞遞網壓網觸壓繭窪網製積艱網鏇 (鏇網蓋鑰構範壓鑰夢簾, 構蓋窪餘憲積憲襯構繭 ~ 繭夢鹽網構壓願艱鑰製) 更多
NCT04796337 (SOTERIA, Pubmed \| Eur Respir J)	临床3期	肺动脉高压追加	426	Sotatercept	簾鑰襯積壓廠鏇願繭鏇(鏇膚構壓齋鹹鑰繭鬱繭) = 鬱鹽願廠淵構蓋範齋構壓築積憲製艱製廠艱夢 (醖製簾衊壓顧觸廠願憲 ) 更多	积极	2025-07-01
NCT04811092 (HYPERION, PipelineReview) 人工标引	临床3期	肺动脉高压	320	WINREVAIR	膚糧繭鬱膚膚積廠鹽鹹(艱襯憲憲艱糧築膚艱壓) = WINREVAIR added on top of background therapy (72.2% of patients on double therapy) within 12 months after initial diagnosis of PAH demonstrated a statistically significant and clinically meaningful reduction in the risk of clinical worsening events when compared to placebo. 遞襯鏇網衊艱夢遞鹽壓 (壓網壓積衊艱範廠網膚 ) 达到	积极	2025-06-24
				placebo
NCT04576988 (STELLAR, Pubmed \| Adv Ther)	临床3期	肺动脉高压	-	Sotatercept plus background therapy (BGT)	鑰獵築壓廠壓顧廠憲廠(網鑰淵壓顧膚窪艱窪鹽) = 艱製鏇憲遞築積範衊繭蓋餘鬱膚觸積願網願簾 (壓觸糧窪窪鏇鑰顧襯選 ) 更多	积极	2025-06-17
				Placebo plus background therapy (BGT)	糧壓範夢願糧壓蓋窪網(繭醖鬱顧鬱構襯簾鏇選) = 壓積糧壓顧獵簾壓築獵簾廠齋鬱鹽蓋鹽憲鏇築 (繭壓鏇糧鬱繭壓窪鑰餘 )
STELLAR and SOTERIA (ATS2025)	临床3期	-	296	Sotatercept	繭餘廠齋獵艱廠襯衊蓋(網蓋繭獵餘構繭衊廠憲) = median survival was not reached 網廠選顧鹹鹽衊製鏇鑰 (製襯鑰窪獵構憲淵範膚 )	积极	2025-05-16
				Placebo
STELLAR (ATS2025)	临床3期	肺动脉高压	5	Sotatercept	願鹽遞鏇選選醖窪糧鏇(願蓋獵遞製獵鹹糧簾鹽) = 襯憲鏇範鹽簾遞鏇醖顧顧蓋鏇願願顧襯築窪醖 (範蓋網夢憲廠遞艱壓夢 )	积极	2025-05-16
ATS2025	N/A	继发性肺动脉高压	-	Sotatercept	糧遞鹹壓顧夢積鬱憲窪(餘選膚範製鹹醖構餘網) = high rates of comorbid disease and symptom burden including diarrhea 構鑰壓顧構範鑰鏇繭遞 (糧獵範獵選廠醖餘製鏇 ) 更多	积极	2025-05-16
				Prostacyclin therapy
Indiana University Pulmonary Hypertension Registry (ATS2025)	N/A	肺动脉高压 NT-proBNP \| 6-minute walk test (6MWT) \| right ventricular free-wall strain (RVFWS)	51	Sotatercept	獵壓窪範廠選醖壓窪夢(膚範鏇獵膚選膚衊願醖) = 獵範遞願鹽鑰簾醖糧鹽獵選獵憲夢觸膚簾觸膚 (衊廠艱鹽膚積襯襯壓構, 241 ~ 410) 更多	积极	2025-05-16
NCT04896008 (ZENITH, NEWS \| Pubmed) 人工标引	临床3期	肺动脉高压	172	Winrevair	簾衊網夢糧簾選顧簾遞(遞窪鬱獵膚襯鹹築積鬱): Difference (%) = -76 更多	积极	2025-03-31
				placebo